Kyle graduated with a BS in Chemistry and a BS in Biological Sciences in 2012 from the University of California Irvine, where her started his research career studying deuterium isotope effects in vivo with Prof. AJ Shaka. Kyle then received his PhD in Biophysical Chemistry from Yale University in 2019. At Yale, his work was performed in the laboratory of Prof. J Patrick Loria studying protein conformational dynamics by solution Nuclear Magnetic Resonance (NMR), where he was an NIH Training grant recipient and an NCI pre-doctoral research fellow. Kyle’s dissertation in DNA polymerases and how these mutations reduce the efficacy of base pair selection greatly enhancing coding errors using DNA polymerase beta as a model system. From Yale, Kyle began his postdoctoral research at Brown University with Prof. George Lisi coupling solution NMR with molecular dynamics and computational chemistry to study allostery in CRISPR-Cas9 and other large molecular assemblies that are generally intractable by protein NMR alone. In 2021, he accepted a position as a scientist in the biophysics group of the Discovery Chemistry Research & Technology organization at Eli Lilly and Company in Indianapolis, Indiana. He is now a Senior Advisor in Chemistry leading biophysical, ligand NMR, and protein NMR efforts to identify novel ligands for small molecule drug discovery across therapeutic areas.
